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Background: Chronic heart failure, is increasing due to the aging population and improvements in heart
disease detection and management. The prevalence is estimated at ~10% of the French general practice
patient population over 59 years old. The primary objective of this study is to improve the quality of life for
heart failure patients though a complex intervention involving patient and general practitioner (GP) education
in primary care.
Methods: A randomised, cluster controlled trial, stratified over 4 areas of the Auvergne region in France
comparing intervention and control groups. The inclusion criteria are: patients older than 50 years with New York
Heart Association (NYHA) stage I, II, or III heart failure, with reduced ejection fraction or with preserved ejection
fraction. Heart failure should be confirmed by the patient’s cardiologist according to the European Society of
Cardiology guidelines criteria. The exclusion criteria include: severe cognitive disorders, living in an institution,
participating in another clinical trial, having NYHA stage IV heart failure, or a lack of French language skills. The
complex intervention consists of training at the GP practice with an interactive 2-day workshop to provide a
patient’s education programme. GPs are trained to perform case management, lifestyle counselling and motivational
interviewing, to educate patients on the main topics including clinical alarm signs, physical activity, diet and
cardiovascular risk factors. The patients’ education sessions are scheduled at 1, 4, 7, 10, 13 and 19 months following the
start of the trial. The primary outcome to be assessed is the impact on the quality of life as determined using two
questionnaires: the Minnesota Living with Heart Failure Questionnaire and SF-36. To detect a difference in the mean
quality of life at 19 months, we anticipate studying a minimum of 400 patients from 80 GPs.
Discussion: This trial will provide insight into the effectiveness of a complex intervention to educate patients with
heart failure including a 2-day GP workshop and patients’ education programme in the setting of a GP consultation to
improve the quality of life in patients with chronic heart failure. This complex intervention tool could be used during
initial and further medical training.
Trial registration: ETIC is a cluster-randomised, controlled trial registered on ClinicalTrials.gov [NCT01065142, 2010,
Feb 8] and the French drug agency [Agence Nationale de Sécurité du Médicament et des produits de santé;
registration number: 2009-A01142-55, on March 5th, 2010].
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Chronic heart failure (CHF) is a common pathology in-
creasing in prevalence due to the aging of the population
and detection and improvements in heart disease man-
agement [1]. Approximately 10% of the French general
practice patient population over 59 years old [2] has
CHF. Patients with CHF have poor quality of life due to
their symptoms and recurrent hospitalisations, and due
to its high complication rates CHF is expensive to treat
[3]. Every year in France there are approximately 200
000 hospitalisations due to CHF which accounts for
1.5% of global health expenditure [4]. The European
Society of Cardiology guidelines recommend pharmaco-
logical therapy to reduce morbidity, mortality and im-
prove patient quality of life; and non-pharmacological
management (self-care, behavioural and patient educa-
tion) to improve adherence to treatment and quality of
life [5].
The results from a meta-analysis have shown that the
implementation of comprehensive disease management
programmes leads to a significant reduction in mortality
(odds-ratio (OR) = 0.80), reduced hospitalisation for car-
diac failure (OR = 0.76) and all illnesses (OR = 0.58) [6].
In France, some studies have assessed the impact of edu-
cation for patients with CHF [7,8]. The interventions
were delivered by multidisciplinary teams, including out-
patient clinics attached to hospitals, which does not re-
flect the French primary care setting where most general
practitioners (GPs) work single-handed. There have been
very few studies exclusively focused on assessing the ef-
fect of CHF management programmes in a primary care
setting, but several including primary care situations
amongst others [9-13]. Other studies have been con-
ducted in primary care but the interventions were not
carried out by the GPs themselves: i.e. patient recruit-
ment occurred in primary care but the intervention was
conducted by nurses or doctors’ assistants [14,15]. More
evidence is needed in primary care because the general-
isability of hospital- or outpatient-based programmes to
primary care is limited.
Therefore we want to assess the effectiveness of a
complex intervention that incorporates education of pa-
tients with CHF by GP’s trained to promote self-care
management and behaviour management. The aim of
the ETIC trial (Education Thérapeutique des patients
Insuffisants Cardiaques/Therapeutic Education for patients
with Cardiac Failure) is to improve the quality of life of
patients with heart failure though a complex intervention
involving patient and GP education in primary care. The
secondary objectives are to assess the effects of the training
on: all-cause and heart-failure (HF)-associated mortality;
all-cause and HF-associated hospitalisation; the cumulative
number of all cause death and HF hospitalisations; adher-
ence to treatment; changes in NYHA heart failure stage;changes weight and body mass index (BMI) and treatment
for a follow-up period of 19 months.
Methods
Study design and randomisation
The global study design is presented in Figure 1. ETIC is
a cluster-randomised, controlled clinical trial with gen-
eral practices as the unit of randomisation (Figure 2).
The randomisation list was drawn up with the software
Stata, version 10 (StataCorp, College Station, Texas, US)
by the biostatistician before the start of the trial. A clus-
ter design was chosen for pragmatic reasons and to
avoid contamination bias. All GPs who volunteered were
randomised and the patients did not know to which
group their GP had been assigned. GPs that were located
within the same practice represented a cluster and such
GPs were placed in the same group to avoid cross-
contamination. The trial is being carried out across the
Auvergne in France, with stratification according to the
4 departments (administrative areas) in this region.
Inclusion and exclusion criteria
Inclusion criteria
Patients older >50 years, with New York Heart Associ-
ation (NYHA) stage I, II or III CHF with reduced ejec-
tion fraction (HFrEF) or preserved ejection fraction
(HFpEF) are eligible for inclusion. Heart failure has to
be documented and confirmed by the patient’s cardiolo-
gist according to the European Society of Cardiology
guidelines, namely, patients have, currently or in the
past, symptoms, signs of fluid retention and objective
evidence of an abnormality of the structure or function
of the heart at rest confirmed by echocardiographic cri-
teria [5]. When GPs recruit patients, patients’ cardiolo-
gists are sent a letter to ask them to confirm heart
failure according these guidelines.
Exclusion criteria
Patients that suffer from severe cognitive disorders (as
judged by the GP), who are living in an institution at the
time of inclusion, are participating in another clinical
trial, have NYHA stage IV heart failure, or a lack of
French language skills are excluded from participating in
the trial.
Instruments and outcomes
The primary outcome is the patients’ quality of life as
measured by SF-36 [16] and the Minnesota Living with
Heart Failure Questionnaire (MLHFQ) [17]. The SF-36
is a generic measure of health impairment, with scores
ranging from 0 to 100: zero indicates the worst quality
of life and 100 the best. The MLHFQ is specific for
chronic heart failure and has 21 questions with scores
ranging from 0 to 105: zero indicates best quality of life
Figure 1 Overview of ETIC study protocol.
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and at 7, 13 and 19 months by the patients, or their
main caregiver, within 7 days of their appointment with
their GP. A score of < 24 on the MLHFQ signifies a good
quality of life, a score between 24 and 45 signifies a
moderate quality of life, and a score > 45 signifies a poor
quality of life [18]. We will assess these cut-off scores to
interpret results in clinical terms. We were unable to
find published cut-off information for the SF-36 health
scores.
The secondary outcomes are: all-cause and heart-
failure-associated mortality; all-cause and heart-failure-
associated hospitalization, number of days in hospital;
the cumulative number of all cause death or HF hospi-
talizations and the cumulative number of days of hospi-
talisation; adherence with therapy; evolution of NYHA
heart failure stage; evolution of treatment; and changes
in weight and body mass index (BMI) at 19 months. We
will assess guideline adherence of treatment at baselineand during the follow-up period. Patient adherence with
therapy will be assessed by the patients themselves with
a self-administrated questionnaire (validated in French)
at baseline and at the end of follow-up period [19].
Should the planned follow-up appointment be missed,
the reason is identified and categorised as follows: lost-
to-follow-up; death; unable to attend for another reason.
Hospitalisations and mortality will be recorded by GPs
at each planned visiting case report form.
GP recruitment and patient enrolment
GPs are eligible to participate in the trial if they provide
in their practice standard care as opposed to exclusively
providing alternative medicine such as acupuncture or
homeopathy. Participating GPs must sign an informed
consent form and agree to implement the study protocol.
Potentially eligible GPs are identified via the Regional
Primary Care Physician Association with an address
database.
Figure 2 ETIC trial flow chart.
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ask them to participate. The GPs recruit the first eligible
patients to participate in the clinical trial until they have
included at least five patients. The inclusion period lasts
one year. The GPs in the two groups receive the same
compensation for their participation. The GP shares an
information sheet and a consent form with the patients.
During the inclusion visit, the GP explains the aim of
the clinical trial, i.e. understand and improve treatment
of patients with heart failure, without describing the ob-
jectives. Patients willing to participate sign the consent
form at home within seven days of the visit and send it
to the data management centre with the first two quality
of life questionnaires.
Intervention group
No medication is tested in this trial and the GPs are
allowed to adapt patients’ treatment if necessary. The
complex intervention consists of training at the GP
practice with an interactive 2-day workshop to provide a
patient’s education programme.
GP training
At an interactive 2-day workshop, GPs assigned to the
intervention group are trained to perform case manage-
ment and educate patients (Table 1). The two-day work-
shop includes the following elements: information on
the case report forms and the patients’ inclusion/exclu-
sion criteria, information on CHF (epidemiology, NYHA
stages, treatment, patient adherence etc.) based on The
European Society of Cardiology guidelines [5], informationon patient education concepts, principles of GP-patient-
communication, lifestyle counselling and motivational
interviewing based on the 5As model (ask, assess, advise,
assist and arrange) [20] and the use of several case vi-
gnettes simulating GP- patient consultations. GPs are
trained to educate patients on the main topics of clinical
alarm signs, physical activity, diet and cardiovascular risk
factors. During the 2-day workshop, GPs are trained by ex-
perts: a nutritionist, an endocrinologist, a cardiologist,
three GPs and a pharmacist, who are all patient education
trainers and one has a Masters degree in patient education.
Patient’s intervention level
The patients’ education sessions will be performed by
their own GPs. The education sessions are standardised
both in their timing, every three months (Figure 1), and
topics covered (Table 2). GPs have an education booklet
in their case report form with the topics covered and
education tools (ie dietary leaflets, clinical alarm signs)
(Additional file 1). The first educational session (educa-
tional diagnosis) for the patient occurs at month one
(Figure 1) and covers several topics: life-style and dietary
habits, physical activity, hobbies, leisure activities, projects
and details resources available for patients (Additional
file 2). This first step is necessary to establish existing
knowledge, attitudes and motivation. Patients have four
further education sessions at 4, 7, 10 and 13 months
followed by an overview session six months after the last
education session at month 19.
Patient education sessions (at 4, 7, 10, 13, 19 months)
are based on patient’s experience and knowledge of their
Table 1 Training seminar for general practitioners: 2-day workshop
Module 1: Introduction - Introduction to the concepts of the ETIC trial and patient education
Module 2: Heart failure
- Chronic heart failure: definitions; epidemiology; clinical diagnosis; treatment guidelines∗;
echocardiographic criteria; cardiac biomarkers: B-type natriuretic peptide (BNP) and NT-proBNP
(how, when to prescribe them, how to use them)
- Clinical symptoms: how to recognize heart failure in daily practice?
- NYHA stages: definitions, assessment of NYHA stages from case vignettes
- Suspicious clinical signs
- Adaptation of physical activity as a function of the NYHA stage
Module 3: Concepts of patient education
- Assessment and building on the patient’s previous knowledge
- Identification of life-style and dietary habits, physical activity, hobbies, leisure activities, projects, and
resources available to the patient
- Assessment of the patient’s stage of change, motivation and attitudes





- Lifestyle counselling based on the 5As model (ask, assess, advise, assist, and arrange)
Module 5: Role-playing to simulate a patient
consultation with the general practitioner
- Identification and use of the patient’s knowledge (clinical alarm signs, physical activity, diet and
cardiovascular risk factors), values, motivation, projects and resources to implicate the patient in
their personal objectives
- Classification of the personal objectives by therapeutic priority and patient preference
- Use of effective communication strategies
Module 6: Case report forms
- Inclusion and exclusion criteria
- How to promote and present the ETIC trial to patients
- How to fill in the case report forms
- How to organize the follow-up and topics: educational booklet and educational tools
(i.e. dietary leaflets, clinical alarm signs)
∗Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen
M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the
Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with
the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388-442.
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diet and cardiovascular risk factors. Patient education
sessions are adapted for each patient, based on the first
education session, one month after inclusion and at each
of the following visits to match the needs and motivation
of each patient. As this is a pragmatic trial aiming to as-
sess the impact of an educational programme in daily
clinical practice, the delivery of the program is allowed
to vary between health care providers. The health care
providers have the flexibility to adapt the programme
according to patients’ needs. For example, if a patient
smokes but does not want to discuss this, this is
respected but, at the following visit, the patient is asked
again if they want to discuss their smoking habits [21].
After each education session, GPs write in their case re-
port form which topics they explored (Additional file 3).
At the end of each visit, patients fix their own personal
objectives with the GP, for example, only eat cooked
pork meat products twice a week, verify weight once aweek and walk their dog once a week (Additional file 3).
These objectives are evaluated at the following patient
education session and can be modified and adapted at
each visit. This continuous evaluation of patients’ needs
and objectives provides the basis for further education ses-
sions. The GPs are trained to manage their own education
objectives (i.e. HTA, diet, adherence, etc.) and patient ob-
jectives (i.e. to be able to walk their grandchildren to
school). They simulate several patient education sessions
during the 2-day workshop. GPs have case report forms
with written standardised instructions for the programme
patient education sessions and to summarise each consult-
ation and write personal patient objectives.
Control group
The GPs in the control group attend a three-hour infor-
mation evening session to learn about the case report
forms and the patients’ inclusion/exclusion criteria.
Their patients have the same schedule for visits as those
able 2 Education intervention topics
nowledge, attitudes
nd motivation
- Do you suffer from heart failure?
- What is « heart failure » for you?
- What do you know about heart failure?
- How do you live with this disease?
- What impact heart failure has on your life
(personal, professional, social)?
- What are your fears?
-What are your expectations?
linical alarm signs
- For you, what could be a clinical alarm sign
of your heart failure?
- What should you do to detect clinical
alarm signs?
- Do you know what to do if you detect
clinical alarm signs?
hysical activity
- What does physical activity mean for you?
- What is yours? Household?, leisure
(e.g. gardening)? Transportation
(e.g. walking, car)?
- When are you breathless? (NYHA)?
- What would you be ready to change in
your habits?
iet
- Where do you eat yours meals?
- Who does the cooking?
- High salt food: what do you know about?
What is your comsumption? What is your
point of view, what changes are you ready
to start?
- BMI ≥ 30 : diet mistakes (snack food,
overeating) or diet troubles ?
- BMI ≤ 18 adult patients or 21 ealderly
patients : diet mistakes or diet troubles ?
here is no predetermined order, each theme is evoked depending on the
atients’ needs and based on the first education session (Additional file 2).







pin the intervention group (at 1, 4, 7, 10, 13, 19 months)
but without specific education intervention.
Statistical considerations
Sample size calculation and power analysis
The sample size required must accommodate the need
to detect a difference between the intervention and con-
trol groups in the mean quality of life (sample size esti-
mated for each domain of SF-36 and for the MLHFQ
score) of 12 points with 90% power and 5% two-sided
type 1 error taking into account clustering by practice
(intra-cluster correlation considered to be between 0.10
and 0.20) [22], and an estimated 20% dropout rate for
GPs and patients. As there is negligible information in
the literature regarding SF-36 and MLHFQ assessment
in intervention studies, a difference of 12 points was
chosen using Brotons’ work [23] and the recommenda-
tions of Cohen [24] regarding variability of the quality oflife indicators [16]. Estimation of the effect size (ES) can
be achieved by a literature search, expert knowledge or
using pilot studies. It is also possible to explore several
scenarios using conventional effect sizes: small (ES = 0.2),
medium (ES = 0.5) and high (ES = 0.8). Variability in the
quality of life indicators is fixed for MLHFQ and SF-36
and corresponds to an effect size of ≥ 0.6 [17,24]. With
these simulations, it is estimated that 40 general practices
recruiting five patients each are required per group, there-
fore 200 patients per group. Overall, 400 patients from 80
GPs will be recruited.
Statistical analysis
The statistician will be blinded with regard to treatment
allocation. The responses to the questionnaire will be
entered into a customised Access database (Microsoft,
Redmond, Wash, US). Analyses will be made using Stata,
version 13 (StataCorp, College Station, Tex, US). If
necessary, an adjustment to accommodate differences
between the baseline characteristics of the groups will be
made. Continuous data will be presented as mean ± stand-
ard deviation (SD). The comparisons between study
groups will be analysed using Chi-square or Fisher's exact
test for categorical variables, and Student's or Mann–
Whitney tests for quantitative variables, with normality
verified by the Shapiro-Wilk test and homoscedasticity by
the Fisher-Snedecor test. The correlation between SF-36
and MLHFQ will be assessed using Pearson’s correlation co-
efficient. Hierarchical linear regression models with
random-effects levels for practice, individuals within prac-
tices and repeated measurements per individual (slope
and intercept) will be used to estimate the effects of the
intervention on SF-36 and MLHFQ scores for the post-
baseline time points. These models will include an inter-
action factor between both the randomisation group and
the particular time point, and will be adjusted for baseline
SF-36 scores, age, gender, diagnosis, smoking history,
treatment and socioeconomic status. Intra-class correl-
ation coefficients will be presented by group. The second-
ary analyses will compare deaths (overall and due to heart
failure) using Kaplan-Meier estimation and the Cox
proportional-hazards regression model, hospitalisations
(overall and due to heart failure), NYHA stage, treatment,
adherence, weight and obesity between the groups with
longitudinal random-effects models described previ-
ously. Estimation methods developed by Verbeke and
Molenberghs will be used to account for missing data
(GPs and patients) [25].
Ethical considerations
The Institute’s ethics committee (Comité de Protection
des Personnes Sud-Est I) approved the trial protocol on
April 19th, 2010. The French drug agency, (Agence
Nationale de Sécurité du Médicament et des produits de
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with the reference 2009-A01142-55. The study is con-
ducted in compliance with the regulations on patient
confidentiality (Comité consultatif sur le traitement de
l’information en matière de recherche dans le domaine
de la Santé (Advisory Committee on Data Processing for
Matters of Research in the Field of Healthcare) and
Commission Nationale de l’Information et des Libertés
(National Commission for Data Protection) agreements
under the reference 1223379). In compliance with the
extended CONSORT statement for cluster, ETIC was
registered on ClinicalTrials.gov as NCT01065142 [26].
Discussion
ETIC is one of the few trials that involving only GPs
[27]. Although multidisciplinary patient education pro-
grammes are probably more effective [28], the current
healthcare organisation in France makes large-scale im-
plementation of this type of intervention difficult, if not
impossible. The idea behind ETIC is to evaluate a com-
plex intervention including GP’s 2-day workshop and pa-
tient’s education programme in primary care in the
current context of healthcare organisation in France to
implement education into daily routine.
In Europe, most of the published trials regarding pa-
tient education programmes involve hospitalised or
younger patients with a profile which is different from
patients seen in primary care [29]. In a meta-analysis of
randomised controlled trials involving patients with
heart failure [30], the mean age of the patients was
61.4 years. In a recent Italian epidemiological study of
primary care of patients with chronic heart failure, the
mean age was 78.5 years [31]; our study population will
probably have a comparable age.
In the ETIC trial, two different quality of life question-
naires are being used, one generic, the SF-36, and the
other specific for chronic heart failure, the MLHFQ. The
SF-36 questionnaire was chosen because the French ver-
sion has been validated and it evaluates both physical
and mental aspects of the quality of life, taking into
consideration cultural differences [16,32]. The MLHFQ
questionnaire was chosen because it is specific for
patients with CHF, it is also validated in French and it
accommodates psychometric properties [33]. In addition,
it is recommended for initial use in clinical research
[34], has been validated in primary care and is simple
and fast to use [17].
The intervention in ETIC is novel because it is stan-
dardised with the topics generally used (clinical alarm
signs, physical activity, diet and cardiovascular risk factors)
[35], but it also involves a holistic approach, centred on
the patients’ needs and feelings and taking into consider-
ation their comorbidities and the representations of their
disease [36]. The first and subsequent patient educationsessions are based on, respectively, educational diagnosis
and changes in habits, desires and worries about discuss-
ing specific topics, such as smoking habits [21,37].
For instance, one study on 240 patients with a mean
age of 70 years and a majority of NYHA stage III
(96.4%) reported baseline SF-36 mean scores of 45.1 in
the intervention group and 46.8 in the control group
[14]. The baseline MLHFQ mean scores were 42.5 and
42.6, respectively. In another study on 200 patients with
a mean age of 63.5 years and a majority of patients with
NYHA stage II-III (94%; 6% had stage IV), the baseline
MLHFQ mean scores were 64.3 and 62.4 in the inter-
vention and control groups, respectively [10]. In a study
comparing home and hospital follow-up in 280 patients
with a mean age of 71 years and slightly fewer patients
with NYHA stage II-III (85%; 15% had stage IV), the
baseline MLHFQ scores were 48.8 and 46.0, respectively
[11]. In three other studies with 89%, 50% and 80% pa-
tients with NYHA stage III or IV, the mean MLHFQ
scores were 49.3, 51.8, and 44.7, respectively [12,13,23].
Our patients will probably be older, with a better quality
of life than the patients in all these studies because they
are recruited in a primary care setting with NYHA stage
I, II or III.
To our knowledge only one other cluster-randomised
trial that measured the impact of a patient education
programme by GPs has been published [23]. A total of
283 patients (mean = 76.3 years) were included: stage I –
1.8%; stage II – 7%; stage III – 38.9%; and stage IV –
50.5%. The mean MLHFQ score was 49.1 and 49.9 in
the intervention and control groups, respectively.
The frequency of the visits in the ETIC trial, every
3 months, was similar to the standard of care; 87% of pa-
tients with heart failure meet their GP at least four times
a year [38]. However, the educational aspects of the
visits can be difficult for some of the GPs in the inter-
vention group.
This study has limitations. The GP randomisation was
done before the patient inclusions. The patients in the
two groups might be different because the training re-
ceived by the GPs in the intervention group may make
them feel more competent and therefore, more inclined
to include more severely ill patients. To avoid this bias,
we could recruit randomised GPs after they had in-
cluded their patients, using the ‘Zelen’ method [39]. Unfor-
tunately, this has not been possible because the inclusion
period lasts one year and the follow-up 19 months; regard-
ing heart failure patient life expectancy, it would not be
relevant [5].
GPs participating in this study might be interested in
patient education and not be representative of French
GPs. This bias is inherent in any study because GPs
must volunteer to participate. Otherwise, it would be
possible that the usual care group could modify their
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as Hawthorne effect [40].
The power of this study might be too low to detect
differences in mortality, hospitalisations and secondary
outcomes. Our interpretation will not focus only on stat-
istical significance but on the effect size and the magni-
tude of improvement describing the clinical relevance
[41]. Therefore, the statistical analysis plan includes
multivariate analyses with adjustment for differences in
the characteristics between the two groups.
In France, some studies have assessed the impact of
patient education for CHF patients [7,8]. However, these
interventions were delivered from multidisciplinary teams,
associated in part with the hospital. This trial will provide
insight in the effectiveness of a complex intervention in-
cluding a GP’s 2-day workshop and patient’s education
programme in the setting of a GP consultation to improve
the quality of life in patients with chronic heart failure in a
pragmatic approach. This complex intervention could be a
CHF management tool for use during initial and further
medical training.
Trial status
The ETIC study is on-going.
Additional files
Additional file 1: Clinical alarm signs and dietary leaflets. These
leaflets are given to patients.
Additional file 2: First educational session. This document is in case
report form.
Additional file 3: Educational sessions summary. This document is in
case report form.
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